WO2009022652A1 - Peptide dérivé de lck utile pour une thérapie de vaccin contre le cancer sur un patient atteint d'un cancer qui est positif pour un allèle de supertype hla-a3 - Google Patents

Peptide dérivé de lck utile pour une thérapie de vaccin contre le cancer sur un patient atteint d'un cancer qui est positif pour un allèle de supertype hla-a3 Download PDF

Info

Publication number
WO2009022652A1
WO2009022652A1 PCT/JP2008/064317 JP2008064317W WO2009022652A1 WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1 JP 2008064317 W JP2008064317 W JP 2008064317W WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1
Authority
WO
WIPO (PCT)
Prior art keywords
hla
lck
positive
cancer
derived peptide
Prior art date
Application number
PCT/JP2008/064317
Other languages
English (en)
Japanese (ja)
Inventor
Kyogo Itoh
Masanori Noguchi
Mamoru Harada
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Priority to JP2009528113A priority Critical patent/JP4972691B2/ja
Publication of WO2009022652A1 publication Critical patent/WO2009022652A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur un peptide issu de Lck qui est utile pour le traitement ou la prévention d'un patient atteint d'un cancer qui est positif pour un allèle de supertype HLA-A3. De façon précise, l'invention porte sur des peptides de Lck90-99, Lck449-458 et Lck450-458 (SEQ ID NO: 4, 17 et 18). Ces peptides peuvent se lier à une molécule d'allèle de supertype HLA-A3 et présentent une aptitude à induire CTL spécifique pour un peptide. Ces peptides sont particulièrement utiles pour le traitement d'un patient atteint d'un cancer qui est négatif pour une molécule de HLA-A2 ou HLA-A24 pour laquelle de nombreux peptides candidats de vaccin contre le cancer ont été identifiés jusque-là.
PCT/JP2008/064317 2007-08-16 2008-08-08 Peptide dérivé de lck utile pour une thérapie de vaccin contre le cancer sur un patient atteint d'un cancer qui est positif pour un allèle de supertype hla-a3 WO2009022652A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528113A JP4972691B2 (ja) 2007-08-16 2008-08-08 ＨＬＡ−Ａ３スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なＬｃｋ由来ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007212179 2007-08-16
JP2007-212179 2007-08-16

Publications (1)

Publication Number Publication Date
WO2009022652A1 true WO2009022652A1 (fr) 2009-02-19

Family

ID=40350705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064317 WO2009022652A1 (fr) 2007-08-16 2008-08-08 Peptide dérivé de lck utile pour une thérapie de vaccin contre le cancer sur un patient atteint d'un cancer qui est positif pour un allèle de supertype hla-a3

Country Status (2)

Country Link
JP (1) JP4972691B2 (fr)
WO (1) WO2009022652A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060235A1 (fr) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 Nouveau peptide à quatre épitopes ctl
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2016060710A (ja) * 2014-09-17 2016-04-25 学校法人近畿大学 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
JP2016065027A (ja) * 2014-09-26 2016-04-28 学校法人近畿大学 Ｈｌａ−ａ３スーパータイプアレル陽性の前立腺癌患者に対する癌ワクチン療法に有用なｅｚｈ２由来ペプチド
EP3360886A4 (fr) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. Peptide dérivé de foxm1 et vaccin le contenant
WO2020004622A1 (fr) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 Agent antitumoral et sa méthode d'évaluation
WO2021132550A1 (fr) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 Agent de thérapie adjuvante post-opératoire

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARASHIMA N ET AL: "Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T Lymphocytes of cancer patients with distant metastases", EUR. J. IMMUNOL, vol. 31, no. 2, 2001, pages 323 - 332, XP002212358 *
IMAI N ET AL: "Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases", INT. J. CANCER, vol. 94, no. 2, 2001, pages 237 - 242, XP002212565 *
MATSUEDA S ET AL: "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles", CLIN. CANCER RES., vol. 11, no. 19, 2005, pages 6933 - 6943, XP003004983 *
MINAMI T ET AL: "Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles", CANCER IMMUNOL. IMMUNOTHER, vol. 56, no. 5, May 2007 (2007-05-01), pages 689 - 698, XP019489780 *
NAITO M ET AL: "Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles", BR. J. CANCER, vol. 97, no. 12, 2007, pages 1648 - 1654 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642900B2 (en) 2007-09-18 2017-05-09 Green Peptide Co., Ltd. CTL inducer composition
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2017171678A (ja) * 2013-10-21 2017-09-28 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
CN105658673A (zh) * 2013-10-21 2016-06-08 大鹏药品工业株式会社 新型的具有4个连接的ctl表位的肽
JPWO2015060235A1 (ja) * 2013-10-21 2017-03-09 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
CN105658673B (zh) * 2013-10-21 2019-07-26 大鹏药品工业株式会社 新型的具有4个连接的ctl表位的肽
AU2014337643B2 (en) * 2013-10-21 2017-07-13 Taiho Pharmaceutical Co., Ltd. Novel four-CTL epitope-joined peptide
WO2015060235A1 (fr) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 Nouveau peptide à quatre épitopes ctl
JP2016060710A (ja) * 2014-09-17 2016-04-25 学校法人近畿大学 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
JP2016065027A (ja) * 2014-09-26 2016-04-28 学校法人近畿大学 Ｈｌａ−ａ３スーパータイプアレル陽性の前立腺癌患者に対する癌ワクチン療法に有用なｅｚｈ２由来ペプチド
EP3360886A4 (fr) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. Peptide dérivé de foxm1 et vaccin le contenant
AU2016335731B2 (en) * 2015-10-08 2021-05-06 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
US11242365B2 (en) 2015-10-08 2022-02-08 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
EP4219525A3 (fr) * 2015-10-08 2023-09-27 OncoTherapy Science, Inc. Peptide dérivé de foxm1 et vaccin le contenant
WO2020004622A1 (fr) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 Agent antitumoral et sa méthode d'évaluation
WO2021132550A1 (fr) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 Agent de thérapie adjuvante post-opératoire

Also Published As

Publication number Publication date
JPWO2009022652A1 (ja) 2010-11-18
JP4972691B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
WO2009022652A1 (fr) Peptide dérivé de lck utile pour une thérapie de vaccin contre le cancer sur un patient atteint d'un cancer qui est positif pour un allèle de supertype hla-a3
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO2006081826A3 (fr) Vaccin a base de peptide de survivine
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
PH12014501083A1 (en) Anticancer fusion protein
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2007009894A3 (fr) Nouveaux peptides utilises dans le traitement de l'obesite
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX337436B (es) Proteina de funsion anticancer.
WO2009038026A1 (fr) Composition inductrice de lymphocytes t cytotoxiques
WO2009072610A1 (fr) Composition de vaccin contre le cancer
HK1144305A1 (zh) 衍生自 的癌抗原肽
DK2137301T3 (da) Adenovirus med mutationer i det endoplasmatiske reticulums retentionsdomæne for E3-19K-proteinet samt deres anvendelse ved cancerbehandling
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2006023598A3 (fr) Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
BRPI0713731B8 (pt) agente indutor de imunidade direcionado contra cânceres, medicamento para tratar e/ou prevenir tumores, e, agente para induzir células
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
WO2008129422A8 (fr) Facteur viii recombinant démannosylé pour le traitement de patients atteint d'une hémophilie a
NZ594198A (en) Neil3 peptides and vaccines including the same
WO2005123760A3 (fr) Traitement du cancer
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP1908826A4 (fr) Peptide dérivé d'une protéine de la prostate en tant que vaccin potentiel pour le cancer pour des patients souffrant d'un cancer de la prostate positifs à la molécule allélique de super-type hla-a3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009528113

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1